3 research outputs found
<i>N</i>‑Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization
We report here a series of 27 10-(4-phenylpiperazin-1-yl)methanones
derived from tricyclic heterocycles which were screened for effects
on tumor cell growth, inhibition of tubulin polymerization, and induction
of cell cycle arrest. Several analogues, among them the 10-(4-(3-methoxyphenyl)piperazine-1-carbonyl)-10<i>H</i>-phenoxazine-3-carbonitrile (<b>16o</b>), showed
excellent antiproliferative properties, with low nanomolar GI<sub>50</sub> values (<b>16o</b>, mean GI<sub>50</sub> of 3.3 nM)
against a large number (93) of cancer cell lines. Fifteen compounds
potently inhibited tubulin polymerization. Analysis of cell cycle
by flow cytometry revealed that inhibition of tumor cell growth was
related to an induction of G2/M phase cell cycle blockade. Western
blotting and molecular docking studies suggested that these compounds
bind efficiently to β-tubulin at the colchicine binding site.
Our studies demonstrate the suitability of the phenoxazine and phenothiazine
core and also of the phenylpiperazine moiety for the development of
novel and potent tubulin polymerization inhibitors
Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19
BACKGROUND The extent to which health care systems have adapted to the COVID-19 pandemic to provide necessary cardiac diagnostic services is unknown.OBJECTIVES The aim of this study was to determine the impact of the pandemic on cardiac testing practices, volumes and types of diagnostic services, and perceived psychological stress to health care providers worldwide.METHODS The International Atomic Energy Agency conducted a worldwide survey assessing alterations from baseline in cardiovascular diagnostic care at the pandemic's onset and 1 year later. Multivariable regression was used to determine factors associated with procedure volume recovery.RESULTS Surveys were submitted from 669 centers in 107 countries. Worldwide reduction in cardiac procedure volumes of 64% from March 2019 to April 2020 recovered by April 2021 in high- and upper middle-income countries (recovery rates of 108% and 99%) but remained depressed in lower middle- and low-income countries (46% and 30% recovery). Although stress testing was used 12% less frequently in 2021 than in 2019, coronary computed tomographic angiography was used 14% more, a trend also seen for other advanced cardiac imaging modalities (positron emission tomography and magnetic resonance; 22%-25% increases). Pandemic-related psychological stress was estimated to have affected nearly 40% of staff, impacting patient care at 78% of sites. In multivariable regression, only lower-income status and physicians' psychological stress were significant in predicting recovery of cardiac testing.CONCLUSIONS Cardiac diagnostic testing has yet to recover to prepandemic levels in lower-income countries. Worldwide, the decrease in standard stress testing is offset by greater use of advanced cardiac imaging modalities. Pandemic-related psychological stress among providers is widespread and associated with poor recovery of cardiac testing. (C) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation